TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Practical Health Co-operation - a Randomised Controlled Intervention Study. The Impact of a Referral Template on Quality of Care and Health Care Co-operation Between Primary and Secondary Care
Brief Summary: The purpose of this study is to examine whether the implementation of a referral template will increase quality of health care delivered and the quality of health care co-operation. The investigators intent to implement a referral template, at the level of the general practitioner (GP), for the referral of patients within 4 separate diagnostic groups:

* dyspepsia/upper GI symptoms
* colonic cancer investigation/lower GI symptoms
* chronic obstructive pulmonary disease (COPD)
* chest pain

Local GP clinics will be randomised to use the referral template or to use standard referral practice. Using a predefined set of quality criteria the investigators will score the process of care in each patient, and compare intervention and control groups. In addition other criteria will be collected and compared between the two groups, e.g.

* time to diagnosis/treatment
* quality of referral
* more appropriate referrals
* patient satisfaction (as measured by a questionnaire)

The investigators hypothesize that the implementation of a referral template will lead to a measurable increase in the quality of health care delivered.


Options:
A: Arm Label: Referral template; Type: EXPERIMENTAL; Interventions: Other: Implementation of referral template | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Implementation of referral template; Assigned to Arm(s): Referral template
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Device: half-yearly monitoring routine | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: half-yearly monitoring routine; Assigned to Arm(s): A
C: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Other: Shared decision making | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Shared decision making; Assigned to Arm(s): Experimental group
D: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Active implementation of a guideline for chronic disease | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: External control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Active implementation of a guideline for chronic disease; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multiple Dose, Randomised, Double-blind, Placebo Controlled, 2 Period Crossover Clinical Trial to Assess the Effect of Aclidinium Bromide 400 μg BID on Exercise Endurance in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Brief Summary: The aim of the present study is to evaluate the effect of aclidinium bromide 400 μg twice a day (BID) administered twice a day versus placebo on exercise endurance and on hyperinflation and dyspnoea at rest and during exercise after 3 weeks of treatment.


Options:
A: Arm Label: Aclidinium bromide; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): Aclidinium bromide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Urban training Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Urban training | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Urban training; Assigned to Arm(s): Urban training Intervention
C: Arm Label: Aclidinium bromide; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium Bromide; Assigned to Arm(s): Aclidinium bromide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Usual Care; Type: OTHER; Interventions: Other: Usual Care | Arm Label: Internet-mediated Walking Program; Type: OTHER; Interventions: Behavioral: automated internet-mediated walking program | Intervention Type: BEHAVIORAL; Name: automated internet-mediated walking program; Assigned to Arm(s): Internet-mediated Walking Program | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Use of Trimo-San Gel for the Prevention of Pessary-associated Bacterial Vaginosis
Brief Summary: The primary objective of this prospective, randomized, controlled study is to assess the effect of Trimo-San vaginal gel on the rate of bacterial vaginosis in women who use pessaries. Women being fitted for a pessary for the first time or not wearing a pessary for \>1 year are recruited in to the study and randomized to using Trimo-San gel daily or not using Trimo-San gel. The investigators use two objective measures of bacterial vaginosis (OSOM BV blue and gram stain) and subjective questionnaires regarding the presence and effect of vaginal symptoms on the pessary user prior to pessary fitting and at 3 months post pessary fitting. The investigators hypothesize that Trimo-San gel with not significantly affect the rate of bacterial vaginosis in pessary wearers as measures by OSOM BV blue and Gram stain, but will have a positive effect on the subjective symptoms experienced by women wearing pessaries.


Options:
A: Arm Label: Premarin cream 0.5gm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vaginal conjugated estrogen cream 0.5gm | Arm Label: Premarin cream 1.0gm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vaginal conjugated estrogen cream 1.0gm | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Vaginal conjugated estrogen cream 0.5gm; Assigned to Arm(s): Premarin cream 0.5gm | Intervention Type: DRUG; Name: Vaginal conjugated estrogen cream 1.0gm; Assigned to Arm(s): Premarin cream 1.0gm
B: Arm Label: Premarin; Type: EXPERIMENTAL; Interventions: Drug: Premarin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Premarin; Assigned to Arm(s): Premarin | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Intravaginal Pessary; Type: EXPERIMENTAL; Interventions: Device: Intravaginal Pessary | Arm Label: Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Therapy | Arm Label: Pessary combined with behavioral therapy; Type: EXPERIMENTAL; Interventions: Device: Pessary combined with behavioral therapy | Intervention Type: BEHAVIORAL; Name: Behavioral Therapy; Assigned to Arm(s): Behavioral Therapy | Intervention Type: DEVICE; Name: Intravaginal Pessary; Assigned to Arm(s): Intravaginal Pessary | Intervention Type: DEVICE; Name: Pessary combined with behavioral therapy; Assigned to Arm(s): Pessary combined with behavioral therapy
D: Arm Label: Trimo-San group; Type: EXPERIMENTAL; Interventions: Drug: Trimo-San gel | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Trimo-San gel; Assigned to Arm(s): Trimo-San group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The ZEroPLASmaTrial (ZEPLAST): a Randomized, Controlled Trial on Transfusion Avoidance in High Transfusion-risk Cardiac Surgery Patients
Brief Summary: Prospective, randomized, double blind trial. The rationale of the study is the concept that fresh frozen plasma (FFP) is still largely used in cardiac surgery, despite the fact that prothrombin complexes and fibrinogen are available.The experimental hypothesis is that cardiac surgery patients may be operated with no use of FFP and with a coagulation factors replacement based on fibrinogen and prothrombin complexes (when needed).

Primary endpoint: Transfusion avoidance Secondary endpoints: Transfusion limitation, massive blood transfusion, bleeding.

Study population: high-risk adult cardiac surgery patients Sample size : 2 groups of 60 patients each


Options:
A: Arm Label: Beriplex® P/N; Type: EXPERIMENTAL; Interventions: Biological: Beriplex® P/N (Kcentra) | Arm Label: Fresh frozen plasma; Type: ACTIVE_COMPARATOR; Interventions: Biological: Fresh frozen plasma | Intervention Type: BIOLOGICAL; Name: Beriplex® P/N (Kcentra); Assigned to Arm(s): Beriplex® P/N | Intervention Type: BIOLOGICAL; Name: Fresh frozen plasma; Assigned to Arm(s): Fresh frozen plasma
B: Arm Label: FXIII17.5IU/Kg; Type: EXPERIMENTAL; Interventions: Drug: catridecacog | Arm Label: FXIII35IU/Kg; Type: EXPERIMENTAL; Interventions: Drug: catridecacog | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: catridecacog; Assigned to Arm(s): FXIII17.5IU/Kg | Intervention Type: DRUG; Name: catridecacog; Assigned to Arm(s): FXIII35IU/Kg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Saline solution; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline solution | Arm Label: Fibrinogen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fibrinogen | Arm Label: Prothrombin complex; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prothrombin complex | Intervention Type: DRUG; Name: Fibrinogen; Assigned to Arm(s): Fibrinogen | Intervention Type: DRUG; Name: Saline solution; Assigned to Arm(s): Saline solution | Intervention Type: DRUG; Name: Prothrombin complex; Assigned to Arm(s): Prothrombin complex
D: Arm Label: Albumin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Human albumin (Placebo) | Arm Label: Haemocomplettan® P; Type: EXPERIMENTAL; Interventions: Drug: Haemocomplettan® P | Intervention Type: DRUG; Name: Haemocomplettan® P; Assigned to Arm(s): Haemocomplettan® P | Intervention Type: DRUG; Name: Human albumin (Placebo); Assigned to Arm(s): Albumin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1 Study of Nivolumab (BMS-936558) Plus Sunitinib, Pazopanib or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma
Brief Summary: The purpose is to determine the safety, effectiveness and best dose to use when giving Nivolumab in combination with Sunitinib, Pazopanib, or Ipilimumab for the treatment of metastatic renal cell carcinoma.


Options:
A: Arm Label: LY2510924 + Sunitinib; Type: EXPERIMENTAL; Interventions: Drug: LY2510924, Drug: Sunitinib | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: LY2510924; Assigned to Arm(s): LY2510924 + Sunitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): LY2510924 + Sunitinib, Sunitinib
B: Arm Label: Arm S: Nivolumab + Sunitinib; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Drug: Sunitinib | Arm Label: Arm P: Nivolumab + Pazopanib; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Pazopanib | Arm Label: Arm I-1: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm I-3: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm IN-3: Nivolumab+Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm I-1: Nivolumab + Ipilimumab, Arm I-3: Nivolumab + Ipilimumab, Arm IN-3: Nivolumab+Ipilimumab, Arm P: Nivolumab + Pazopanib, Arm S: Nivolumab + Sunitinib | Intervention Type: BIOLOGICAL; Name: Pazopanib; Assigned to Arm(s): Arm P: Nivolumab + Pazopanib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Arm S: Nivolumab + Sunitinib | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm I-1: Nivolumab + Ipilimumab, Arm I-3: Nivolumab + Ipilimumab, Arm IN-3: Nivolumab+Ipilimumab
C: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Temsirolimus, Drug: Bevacizumab | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Interferon alpha-2a | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): A, C | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Interferon alpha-2a; Assigned to Arm(s): C

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma
Brief Summary: This study will compare the efficacy of simtuzumab (GS-6624) versus placebo in combination with gemcitabine in adults with pancreatic cancer. The treatment phase of this study will be comprised of 2 sequential parts: an open label treatment phase and a double-blinded treatment phase.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: gemcitabine, Drug: cisplatin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: gemcitabine | Intervention Type: DRUG; Name: gemcitabine; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): A
B: Arm Label: gemcitabine hydrochloride + IMC-C225; Type: EXPERIMENTAL; Interventions: Biological: cetuximab, Drug: gemcitabine hydrochloride | Arm Label: gemcitabine hydrochloride alone; Type: EXPERIMENTAL; Interventions: Drug: gemcitabine hydrochloride | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): gemcitabine hydrochloride + IMC-C225 | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): gemcitabine hydrochloride + IMC-C225, gemcitabine hydrochloride alone
C: Arm Label: Masitinib & gemcitabine; Type: EXPERIMENTAL; Interventions: Drug: Masitinib, Drug: Gemcitabine | Arm Label: Placebo & gemcitabine; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Gemcitabine | Intervention Type: DRUG; Name: Masitinib; Assigned to Arm(s): Masitinib & gemcitabine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo & gemcitabine | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Masitinib & gemcitabine, Placebo & gemcitabine
D: Arm Label: Simtuzumab (open-label); Type: EXPERIMENTAL; Interventions: Drug: Simtuzumab, Drug: Gemcitabine | Arm Label: Simtuzumab 200 mg (randomized); Type: EXPERIMENTAL; Interventions: Drug: Simtuzumab, Drug: Gemcitabine | Arm Label: Simtuzumab 700 mg (randomized); Type: EXPERIMENTAL; Interventions: Drug: Simtuzumab, Drug: Gemcitabine | Arm Label: Placebo (randomized); Type: PLACEBO_COMPARATOR; Interventions: Drug: Gemcitabine, Drug: Placebo to match simtuzumab | Intervention Type: DRUG; Name: Simtuzumab; Assigned to Arm(s): Simtuzumab (open-label), Simtuzumab 200 mg (randomized), Simtuzumab 700 mg (randomized) | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Placebo (randomized), Simtuzumab (open-label), Simtuzumab 200 mg (randomized), Simtuzumab 700 mg (randomized) | Intervention Type: DRUG; Name: Placebo to match simtuzumab; Assigned to Arm(s): Placebo (randomized)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dipeptidyl Peptidase (DPP) IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Patients With Type 2 Diabetes
Brief Summary: A randomized versus placebo trial designed to evaluate the clinical and humoral effects of 4 months of vildagliptin on healing of chronic ulcers in type 2 diabetes.


Options:
A: Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: rosiglitazone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vildagliptin; Type: EXPERIMENTAL; Interventions: Drug: vildagliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): Vildagliptin
C: Arm Label: Lira 1.8; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: placebo | Arm Label: Lira 1.2; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: placebo | Arm Label: Glimepiride - 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: glimepiride, Drug: placebo | Arm Label: Glimepiride - 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: glimepiride, Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.8 | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): Glimepiride - 1, Glimepiride - 2 | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Lira 1.2, Lira 1.8 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Glimepiride - 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Glimepiride - 2
D: Arm Label: Pioglitazone QD; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Arm Label: Placebo QD; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo QD

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Premature Termination of Resuscitation in Survivors of Cardiac Arrest
Brief Summary: The study Premature Termination of Resuscitation in Survivors of Cardiac Arrest focuses on using innovative knowledge translation strategies to improve appropriate neuroprognostication for survivors of cardiac arrest and prevent premature termination of life sustaining therapies. This is important because any early gains achieved during resuscitation will be nullified if clinicians terminate life-sustaining therapies prematurely based on inadequate prognostic information. An effective translation strategy for neuroprognostication will result in improved physician adherence to evidence-based medicine and an increase in the proportion of patients surviving to achieve a good neurological outcome following cardiac arrest.


Options:
A: Arm Label: Adrenaline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adrenaline | Arm Label: Vasopressin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vasopressin | Intervention Type: DRUG; Name: Adrenaline; Assigned to Arm(s): Adrenaline | Intervention Type: DRUG; Name: Vasopressin; Assigned to Arm(s): Vasopressin
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: AutoPulse | Arm Label: 2; Type: OTHER; Interventions: Other: Manual | Intervention Type: DEVICE; Name: AutoPulse; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Manual; Assigned to Arm(s): 2
C: Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Epinephrine, Placebo | Arm Label: Study Group; Type: EXPERIMENTAL; Interventions: Drug: Vasopressin, Epinephrine, and Steroids | Intervention Type: DRUG; Name: Vasopressin, Epinephrine, and Steroids; Assigned to Arm(s): Study Group | Intervention Type: DRUG; Name: Placebo, Epinephrine, Placebo; Assigned to Arm(s): Control Group
D: Arm Label: Active Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Quality improvement | Arm Label: Control Hospitals; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Quality improvement; Assigned to Arm(s): Active Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Placebo-controlled Study of the Effect of LIraglutide on Left VEntricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes (The LIVE-study)
Brief Summary: Type 2 diabetes (T2D) is a major risk factor of chronic heart failure (CHF). Glycemic control in patients with the combination of T2D and CHF is complicated and the currently available treatments have proven to be inadequate in clinical trials.

Objectives To investigate the effect of Liraglutide compared to placebo on left ventricular ejection fraction (LVEF) in CHF patients with and without T2D.

Multicenter, randomized, double blind study of 240 patients with documented systolic CHF (50% with T2DM) will be randomised. The effect of Liraglutide on left ventricular systolic and diastolic function will be evaluated by advanced echocardiography

Primary outcome parameter is change in LVEF from visit 1 to week 24.


Options:
A: Arm Label: Canagliflozin (JNJ-28431754); Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin, 100 mg, Drug: Canagliflozin, 300 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Canagliflozin, 100 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754) | Intervention Type: DRUG; Name: Canagliflozin, 300 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754)
B: Arm Label: Liraglutid; Type: ACTIVE_COMPARATOR; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutid | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Semaglutide; Type: EXPERIMENTAL; Interventions: Drug: Semaglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Semaglutide; Assigned to Arm(s): Semaglutide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Intensive Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intensive lifestyle | Intervention Type: BEHAVIORAL; Name: Intensive lifestyle; Assigned to Arm(s): Intensive Lifestyle | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B